WO2009054439A1 - Pai-1産生抑制剤 - Google Patents

Pai-1産生抑制剤 Download PDF

Info

Publication number
WO2009054439A1
WO2009054439A1 PCT/JP2008/069207 JP2008069207W WO2009054439A1 WO 2009054439 A1 WO2009054439 A1 WO 2009054439A1 JP 2008069207 W JP2008069207 W JP 2008069207W WO 2009054439 A1 WO2009054439 A1 WO 2009054439A1
Authority
WO
WIPO (PCT)
Prior art keywords
pai
group
production inhibitor
benzene ring
alkyl group
Prior art date
Application number
PCT/JP2008/069207
Other languages
English (en)
French (fr)
Inventor
Susumu Muto
Akiko Itai
Original Assignee
Institute Of Medicinal Molecular Design, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute Of Medicinal Molecular Design, Inc. filed Critical Institute Of Medicinal Molecular Design, Inc.
Priority to JP2009538246A priority Critical patent/JP5470046B2/ja
Priority to EP08842108A priority patent/EP2201946A4/en
Priority to AU2008314979A priority patent/AU2008314979A1/en
Priority to BRPI0816560-2A priority patent/BRPI0816560A2/pt
Priority to CN2008801133696A priority patent/CN101842093B/zh
Priority to CA2703494A priority patent/CA2703494A1/en
Publication of WO2009054439A1 publication Critical patent/WO2009054439A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

　下記の一般式(I)で表される化合物は、PAI-1産生抑制作用を有する。 【化１】 （式中、R1は例えば水素原子、4-(モルホルニル)カルボニル基などを表し、環Dは例えばベンゼン環又は置換基を有するベンゼン環を表し、フェニル基Eは例えばハロゲン原子、ハロゲン化アルキル基、アルキル基、ハロゲン化アルコキシ基、アルコキシ基などの置換基を有する。）
PCT/JP2008/069207 2007-10-23 2008-10-23 Pai-1産生抑制剤 WO2009054439A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2009538246A JP5470046B2 (ja) 2007-10-23 2008-10-23 Ｐａｉ−１産生抑制剤
EP08842108A EP2201946A4 (en) 2007-10-23 2008-10-23 HAMMER OF PAI-1 PRODUCTION
AU2008314979A AU2008314979A1 (en) 2007-10-23 2008-10-23 Inhibitor of PAI-1 production
BRPI0816560-2A BRPI0816560A2 (pt) 2007-10-23 2008-10-23 Método de inibição de produção de pai-1 método para prevenção ou melhora de uma doença causada por uma super-produção de pai-1"
CN2008801133696A CN101842093B (zh) 2007-10-23 2008-10-23 Pai-1产生抑制剂
CA2703494A CA2703494A1 (en) 2007-10-23 2008-10-23 Inhibitor of pai-1 production

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007275557 2007-10-23
JP2007-275557 2007-10-23

Publications (1)

Publication Number Publication Date
WO2009054439A1 true WO2009054439A1 (ja) 2009-04-30

Family

ID=40579541

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/069207 WO2009054439A1 (ja) 2007-10-23 2008-10-23 Pai-1産生抑制剤

Country Status (9)

Country Link
EP (1) EP2201946A4 (ja)
JP (1) JP5470046B2 (ja)
KR (1) KR20100097113A (ja)
CN (2) CN102872020A (ja)
AU (1) AU2008314979A1 (ja)
BR (1) BRPI0816560A2 (ja)
CA (1) CA2703494A1 (ja)
RU (1) RU2010120675A (ja)
WO (1) WO2009054439A1 (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013501737A (ja) * 2009-08-14 2013-01-17 バイエル・クロップサイエンス・アーゲー 殺虫性カルボキサミド類
CN107207417A (zh) * 2014-11-13 2017-09-26 埃罗米克斯公司 新方法
US9827253B2 (en) 2013-11-06 2017-11-28 Aeromics, Inc. Prodrug salts
US9994514B2 (en) 2012-05-08 2018-06-12 Aeromics, Inc. Methods of treating cerebral edema and spinal cord edema
WO2024172001A1 (ja) * 2023-02-13 2024-08-22 本岡 知子 抗トリパノソーマ薬

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400142B2 (en) 2015-12-18 2022-08-02 Talengen International Limited Treatment of diabetic nerve injury comprising administering plasminogen
US11090372B2 (en) 2015-12-18 2021-08-17 Talengen International Limited Method of treating diabetic nephropathy comprising administering plasminogen
TWI624267B (zh) 2015-12-18 2018-05-21 Talengen Institute Of Life Sciences Co Ltd 纖溶酶原在製備預防或治療糖尿病性視網膜病變的藥劑上的用途及包括纖溶酶原用於預防或治療糖尿病性視網膜病變之藥劑
CN108778320A (zh) 2015-12-18 2018-11-09 泰伦基国际有限公司 一种预防和治疗心血管病的新方法
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
WO2018107702A1 (zh) * 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种治疗糖尿病的新方法
CN108210900A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗肥胖症的药物及其用途
US11547746B2 (en) 2016-12-15 2023-01-10 Talengen International Limited Method for treating coronary atherosclerosis and complications thereof
CN115504940A (zh) * 2021-06-23 2022-12-23 中国科学院上海药物研究所 一种酰胺类化合物、其制备方法和制药用途
CN113519544A (zh) * 2021-08-27 2021-10-22 皖南医学院 一种植物源杀螨剂及其制备方法和应用

Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62501703A (ja) * 1984-11-29 1987-07-09 イタルファルマコ・エッセ・ピ・ア アミノ−サリチル酸誘導体、その塩、それらの製法およびそれらを含有する医薬組成物
WO1995021832A1 (en) 1994-02-14 1995-08-17 Xenova Limited Pharmaceutical piperazine compounds
WO1995032190A2 (en) 1994-05-24 1995-11-30 Xenova Limited Pharmaceutical diketopiperazine compounds
WO1999065449A2 (en) 1998-06-19 1999-12-23 Smithkline Beecham Corporation INHIBITORS OF TRANSCRIPTION FACTOR NF-λB
WO2002049632A1 (fr) 2000-12-18 2002-06-27 Institute Of Medicinal Molecular Design. Inc. Inhibiteurs de production et de liberation de cytokines inflammatoires
GB2372740A (en) 2001-01-17 2002-09-04 Xenova Ltd Diketopiperazines
WO2003000684A1 (en) 2001-06-20 2003-01-03 Wyeth Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (pai-1)
WO2003000253A1 (en) 2001-06-20 2003-01-03 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2003000258A1 (en) 2001-06-20 2003-01-03 Wyeth Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2003000671A1 (en) 2001-06-20 2003-01-03 Wyeth Naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2003100064A1 (fr) 2002-05-29 2003-12-04 Kyowa Hakko Kogyo Co., Ltd. Nouvelle ubiquitine-ligase
WO2003103654A1 (ja) 2002-06-10 2003-12-18 株式会社医薬分子設計研究所 ＮＦ−κＢ活性化阻害剤
WO2003103658A1 (ja) 2002-06-05 2003-12-18 株式会社医薬分子設計研究所 免疫関連プロテインキナーゼ阻害剤
WO2004052856A1 (en) 2002-12-10 2004-06-24 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2004052893A2 (en) 2002-12-10 2004-06-24 Wyeth Substituted dihydropyrano indole-3,4-dione derivatives and 3-oxoacetic acid substituted 2-hydroxymethylindole derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2005026127A1 (ja) * 2003-09-11 2005-03-24 Institute Of Medicinal Molecular Design. Inc. プラスミノゲンアクチベータインヒビター－１阻害剤
WO2005030192A1 (en) 2003-09-25 2005-04-07 Wyeth 4- (1h-indol-3-yl-methylideneaminoxy-propoxy) -benzioc acid derivatives and related compounds as pai-1 inhibitors for the treatment of impairment of the fibrinolytic system and of thrombisis
WO2005030715A1 (en) 2003-09-25 2005-04-07 Wyeth Substituted sulfonamide-indole-2-carboxylic acid derivatives as pai-1 inhibitors
WO2005030204A1 (en) 2003-09-25 2005-04-07 Wyeth Substituted oxadiazolidinediones as pai-1 inhibitors
WO2005030756A1 (en) 2003-09-25 2005-04-07 Wyeth Substituted pyrrole-indoles as inhibitors of pai-1
WO2005030716A1 (en) 2003-09-25 2005-04-07 Wyeth Heterocyclic- or aryloxy, -thio or -amino substituted indoles-2-carboxylic acids or esters as pai-1
US20050124664A1 (en) 2003-10-30 2005-06-09 Eric Sartori Urea thiadiazole inhibitors of plasminogen activator inhibior-1
US20050124667A1 (en) 2003-10-30 2005-06-09 Eric Sartori Oxamide inhibitors of plasminogen activator inhibitor-1
US20050143384A1 (en) 2003-10-30 2005-06-30 Eric Sartori Amide thiadiazole inhibitors of plasminogen activator inhibitor-1
WO2006095713A1 (ja) * 2005-03-08 2006-09-14 Institute Of Medicinal Molecular Design. Inc. プラスミノゲンアクチベータインヒビター－１阻害剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1493375A (en) * 1974-09-20 1977-11-30 Ici Ltd Salicylanilide derivatives
EA008769B1 (ru) * 2002-06-05 2007-08-31 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Лекарственное средство для лечения диабета
AU2003242108B2 (en) * 2002-06-10 2008-09-11 Institute Of Medicinal Molecular Design, Inc. Medicament for treatment of cancer
WO2006057845A1 (en) * 2004-11-24 2006-06-01 Eli Lilly And Company Aromatic ether derivatives useful as thrombin inhibitors

Patent Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62501703A (ja) * 1984-11-29 1987-07-09 イタルファルマコ・エッセ・ピ・ア アミノ−サリチル酸誘導体、その塩、それらの製法およびそれらを含有する医薬組成物
WO1995021832A1 (en) 1994-02-14 1995-08-17 Xenova Limited Pharmaceutical piperazine compounds
WO1995032190A2 (en) 1994-05-24 1995-11-30 Xenova Limited Pharmaceutical diketopiperazine compounds
WO1999065449A2 (en) 1998-06-19 1999-12-23 Smithkline Beecham Corporation INHIBITORS OF TRANSCRIPTION FACTOR NF-λB
WO2002049632A1 (fr) 2000-12-18 2002-06-27 Institute Of Medicinal Molecular Design. Inc. Inhibiteurs de production et de liberation de cytokines inflammatoires
GB2372740A (en) 2001-01-17 2002-09-04 Xenova Ltd Diketopiperazines
WO2003000684A1 (en) 2001-06-20 2003-01-03 Wyeth Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (pai-1)
WO2003000253A1 (en) 2001-06-20 2003-01-03 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2003000258A1 (en) 2001-06-20 2003-01-03 Wyeth Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2003000671A1 (en) 2001-06-20 2003-01-03 Wyeth Naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2003100064A1 (fr) 2002-05-29 2003-12-04 Kyowa Hakko Kogyo Co., Ltd. Nouvelle ubiquitine-ligase
WO2003103658A1 (ja) 2002-06-05 2003-12-18 株式会社医薬分子設計研究所 免疫関連プロテインキナーゼ阻害剤
WO2003103654A1 (ja) 2002-06-10 2003-12-18 株式会社医薬分子設計研究所 ＮＦ−κＢ活性化阻害剤
WO2004052856A1 (en) 2002-12-10 2004-06-24 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2004052893A2 (en) 2002-12-10 2004-06-24 Wyeth Substituted dihydropyrano indole-3,4-dione derivatives and 3-oxoacetic acid substituted 2-hydroxymethylindole derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2005026127A1 (ja) * 2003-09-11 2005-03-24 Institute Of Medicinal Molecular Design. Inc. プラスミノゲンアクチベータインヒビター－１阻害剤
EP1666469A1 (en) 2003-09-11 2006-06-07 Institute of Medicinal Molecular Design, Inc. Plasminogen activator inhibitor-1 inhibitor
WO2005030204A1 (en) 2003-09-25 2005-04-07 Wyeth Substituted oxadiazolidinediones as pai-1 inhibitors
WO2005030715A1 (en) 2003-09-25 2005-04-07 Wyeth Substituted sulfonamide-indole-2-carboxylic acid derivatives as pai-1 inhibitors
WO2005030756A1 (en) 2003-09-25 2005-04-07 Wyeth Substituted pyrrole-indoles as inhibitors of pai-1
WO2005030716A1 (en) 2003-09-25 2005-04-07 Wyeth Heterocyclic- or aryloxy, -thio or -amino substituted indoles-2-carboxylic acids or esters as pai-1
WO2005030192A1 (en) 2003-09-25 2005-04-07 Wyeth 4- (1h-indol-3-yl-methylideneaminoxy-propoxy) -benzioc acid derivatives and related compounds as pai-1 inhibitors for the treatment of impairment of the fibrinolytic system and of thrombisis
US20050124664A1 (en) 2003-10-30 2005-06-09 Eric Sartori Urea thiadiazole inhibitors of plasminogen activator inhibior-1
US20050124667A1 (en) 2003-10-30 2005-06-09 Eric Sartori Oxamide inhibitors of plasminogen activator inhibitor-1
US20050143384A1 (en) 2003-10-30 2005-06-30 Eric Sartori Amide thiadiazole inhibitors of plasminogen activator inhibitor-1
WO2006095713A1 (ja) * 2005-03-08 2006-09-14 Institute Of Medicinal Molecular Design. Inc. プラスミノゲンアクチベータインヒビター－１阻害剤

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
BIOCHEM. BIOPHYS. RES. COMMUN., vol. 294, no. 5, 2002, pages 1155 - 1160
BIOCHEMISTRY, vol. 37, no. 5, 1998, pages 1227 - 1234
COMP. HEPATOL., vol. 6, 2 May 2007 (2007-05-02), pages 5
FASEB J., vol. 15, no. 10, 2001, pages 1840 - 1842
GEN. DIAGN. PATHOL., vol. 141, no. 1, 1995, pages 41 - 48
J. IMMUNOL., vol. 165, 2000, pages 3154 - 3161
J. IMMUNOL., vol. 165, no. 6, 2000, pages 3154 - 3161
J. MED CHEM., vol. 47, no. 14, 2004, pages 3491 - 3494
MOL. MED., vol. 2, no. 5, 1996, pages 568 - 582
NAT. MED., vol. 4, no. 8, 1998, pages 923 - 928
NATURE, vol. 346, no. 6279, 1990, pages 74 - 76
PATHOBIOLOGY, vol. 71, 2004, pages 295 - 301
PROC. NATL. ACAD. SCI. U. S. A., vol. 89, no. 15, 1992, pages 6998 - 7002
See also references of EP2201946A4 *
SPENCER J. R., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 12, 2002, pages 2023 - 2026, XP008131173 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013501737A (ja) * 2009-08-14 2013-01-17 バイエル・クロップサイエンス・アーゲー 殺虫性カルボキサミド類
US9227923B2 (en) 2009-08-14 2016-01-05 Bayer Intellectual Property Gmbh Pesticidal carboxamides
US9994514B2 (en) 2012-05-08 2018-06-12 Aeromics, Inc. Methods of treating cerebral edema and spinal cord edema
US11084778B2 (en) 2012-05-08 2021-08-10 Aeromics, Inc. Methods of treating cardiac edema, neuromyelitis optica, and hyponatremia
US11873266B2 (en) 2012-05-08 2024-01-16 Aeromics, Inc. Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke
US9827253B2 (en) 2013-11-06 2017-11-28 Aeromics, Inc. Prodrug salts
US10258636B2 (en) 2013-11-06 2019-04-16 Aeromics, Inc. Prodrug salts
US10894055B2 (en) 2013-11-06 2021-01-19 Aeromics, Inc. Pharmaceutical compositions, methods of making pharmaceutical compositions, and kits comprising 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}4-chlorophenyl dihydrogen phosphate
US11071744B2 (en) 2013-11-06 2021-07-27 Aeromics, Inc. Prodrug salts
US11801254B2 (en) 2013-11-06 2023-10-31 Aeromics, Inc. Pharmaceutical compositions and methods of making pharmaceutical compositions comprising 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate
CN107207417A (zh) * 2014-11-13 2017-09-26 埃罗米克斯公司 新方法
WO2024172001A1 (ja) * 2023-02-13 2024-08-22 本岡 知子 抗トリパノソーマ薬

Also Published As

Publication number Publication date
JPWO2009054439A1 (ja) 2011-03-03
AU2008314979A1 (en) 2009-04-30
CA2703494A1 (en) 2009-04-30
BRPI0816560A2 (pt) 2015-09-01
EP2201946A1 (en) 2010-06-30
RU2010120675A (ru) 2011-11-27
CN101842093B (zh) 2012-08-22
KR20100097113A (ko) 2010-09-02
JP5470046B2 (ja) 2014-04-16
CN101842093A (zh) 2010-09-22
CN102872020A (zh) 2013-01-16
EP2201946A4 (en) 2012-01-25

Similar Documents

Publication Publication Date Title
WO2009054439A1 (ja) Pai-1産生抑制剤
WO2008140066A3 (en) Pyridone derivatives as p38a mapk inhibitors
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
TN2011000362A1 (en) Pyridazinone compounds
TNSN08343A1 (en) Polycyclic cinnamide derivative
NO20080942L (no) Amino-5-[4-(difluormetoksy)-fenyl]-5-fenylimidazolonforbindelser som inhibitorer av beta-sekretase (BACE)
WO2007028135A3 (en) Imidazopyridine compounds
WO2008005368A3 (en) Piperazines as p2x7 antagonists
WO2009019015A8 (en) Novel herbicides
WO2009019005A8 (en) Tricyclic bridged cyclopentanedione derivatives as herbicides
WO2007109080A3 (en) Deuterated hepatitis c protease inhibitors
MX2010002243A (es) Derivados fungicidas de 2-alquiltio-2-quinoliniloxi-acetamida.
WO2009001817A1 (ja) １１β－ＨＳＤ１阻害活性を有する化合物
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
WO2008047952A3 (en) Antidepressant, neuroprotectant, amyloid beta deposition inhibitor or age retardant containing heterocyclic compound
WO2009038064A1 (ja) Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有する複素環誘導体
BRPI0813870A2 (pt) Síntese catalisada por metal de transição de 2h-indazóis.
WO2009069736A1 (ja) 含窒素化合物
TW200732295A (en) Selective N-sulfonylation of 2-amino trifluoroalkyl substituted alcohols
WO2007062308A3 (en) Homo- and heterocyclic compounds suitable as cetp inhibitors
EP1726584A4 (en) 2-AMINOCHINAZOLINDERIVAT
TN2010000045A1 (en) Novel herbicides
IN2012DN00770A (ja)
WO2008153129A1 (ja) 尿酸値低下剤
WO2008136378A1 (ja) 新規なスルホンアミド誘導体またはその塩

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880113369.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08842108

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008842108

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008314979

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2009538246

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2703494

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2008314979

Country of ref document: AU

Date of ref document: 20081023

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20107010934

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010120675

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0816560

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100414